India’s Cut-Price Generics Program Rebounds But Real Impact Still Limited

 
• By Anju Ghangurde
  
Indian Medicine
INDIA'S AMBITIOUS CUT-PRICE MEDICINES INITIATIVE STILL HAS A LONG WAY TO GO

More from Policy & Regulation

More from Generics Bulletin